Literature DB >> 8851453

Erythromycin, clarithromycin, and azithromycin: are the differences real?

G W Amsden1.   

Abstract

Erythromycin, clarithromycin, and azithromycin are clinically effective for the treatment of common respiratory and skin/skin-structure infections. Erythromycin and azithromycin are also effective for treatment of nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. Compared with erythromycin, clarithromycin and azithromycin offer improved tolerability. Clarithromycin, however, is more similar to erythromycin in pharmacokinetic measures such as half-life, tissue distribution, and drug interactions. Misunderstandings about differences among the macrolides (erythromycin and clarithromycin) and the azalide (azithromycin) in terms of pharmacokinetics and pharmacodynamics, spectrum of activity, safety, and cost are common. The uptake and release of these compounds by white blood cells and fibroblasts account for differences in tissue half-life, volume of distribution, intracellular:extracellular ratio, and in vivo potency. Although microbiologic studies reveal that gram-positive pathogens are equally susceptible to these agents, significantly more isolates of Haemophilus influenzae are susceptible to azithromycin than to erythromycin or clarithromycin. Concentrations achieved at the infection site and duration above the minimum inhibitory concentration are as important as in vitro activity in determining in vivo activity against bacterial pathogens. Analysis of safety data indicates differences among these agents in drug interactions and use in pregnancy. Analysis of safety data reveals pharmacokinetic drug interactions for erythromycin and clarithromycin with theophylline, terfenadine, and carbamazepine that are not found with azithromycin. Both erythromycin and azithromycin are pregnancy category B drugs; clarithromycin is a category C drug. The numerous differences in pharmacokinetics, microbiology, safety, and costs among erythromycin, clarithromycin, and azithromycin can be used in the judicious selection of treatment for indicated infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851453     DOI: 10.1016/s0149-2918(96)80179-2

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  29 in total

1.  Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers.

Authors:  K W Garey; C A Peloquin; P G Godo; A N Nafziger; G W Amsden
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

3.  Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.

Authors:  Songmao Zheng; Peter Matzneller; Markus Zeitlinger; Stephan Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

4.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Transport of Azithromycin into Extravascular Space in Rats.

Authors:  Shinji Kobuchi; Miki Aoki; Chiaki Inoue; Hiroyuki Murakami; Akiko Kuwahara; Tsutomu Nakamura; Hiroyuki Yasui; Yukako Ito; Kanji Takada; Toshiyuki Sakaeda
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen.

Authors:  Ping Liu; Hameed Allaudeen; Richa Chandra; Kem Phillips; Arvid Jungnik; Jeanne D Breen; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

8.  Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects.

Authors:  T Pene Dumitrescu; T Anic-Milic; K Oreskovic; J Padovan; K L R Brouwer; P Zuo; V D Schmith
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

9.  Macrolides: A Canadian Infectious Disease Society position paper.

Authors:  S McKenna; G Evans
Journal:  Can J Infect Dis       Date:  2001-07

Review 10.  Treating common ear problems in pregnancy: what is safe?

Authors:  Petros V Vlastarakos; Thomas P Nikolopoulos; Leonidas Manolopoulos; Eleftherios Ferekidis; George Kreatsas
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-11-23       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.